2012 Kern Lipid Conference

描述（由申请人提供）：2012年克恩脂质会议将探讨脂质组学，系统生物学和决定心脏代谢风险的因素之间的接口，使研究科学家和实习生在不同学科的工作将在一个真正独特的大学论坛聚集在一起，以解决与重要的健康优先事项相关的研究。克恩 传统上，大会关注的是脂质代谢与血脂异常、动脉粥样硬化和糖尿病等复杂心脏代谢疾病之间的关系，2012年的会议也不例外。会议计划旨在涵盖系统生物学方法在描述复杂心脏代谢疾病病因方面的新作用。在过去的几年里，人们对多组分生物过程的系统生物学方法重新产生了兴趣，如导致2型糖尿病、血脂异常和动脉粥样硬化的病理学。这在一定程度上是由于技术的发展，如表达阵列和下一代测序，这导致了在全球水平上询问生物系统的能力，并为实施治疗复杂疾病的个性化医学方法打开了大门。第二，正在开发新的计算和数学方法，如网络建模，以从高通量和其他数据中提取生物信息。最后，越来越多的人认识到，仅凭还原论的方法，我们无法完全解决常见的心脏病和糖尿病中的遗传和环境相互作用等问题。董事会选择了A博士。Jake Lusis、Margrit施瓦茨和Roger Newton担任会议共同主席。三人都是克恩董事会成员。Lusis博士是洛杉矶的加州大学人类遗传学教授。他的研究主要集中在代谢和心血管疾病的遗传学。Dr.施瓦茨是Amgen，Inc. Atheroscopy的总监。她的兴趣是脂质代谢和心血管疾病。罗杰·牛顿博士是密歇根州普利茅斯EssappTherapeutics的总裁。他的兴趣是药理学和心血管疾病。 公共卫生相关性：本次会议的目标是为与会者提供一个机会，了解脂质组学和系统生物学方法的最新进展，以及听取和讨论其作为研究心脏代谢疾病工具的相关性。

DESCRIPTION (provided by applicant): The 2012 Kern Lipid Conference will explore the interface between lipidomics, systems biology and factors determining cardiometabolic risk so that research scientists and trainees working in diverse disciplines will be brought together in a truly unique and collegiate forum to address research relevant to vital health priorities. The Kern Conference has traditionally focused on the relationships between lipid metabolism and complex cardiometabolic diseases such as dyslipidemia, atherosclerosis and diabetes, and the 2012 meeting will be no exception. The meeting program is designed to cover new information on the emerging role of systems biology approaches for delineating the causes of complex cardiometabolic diseases. The last several years have witnessed a revival in interest in systems biology approaches to multicomponent, biologic processes such as the pathologies leading to type 2 diabetes, dyslipidemias and atherosclerosis. This is, in part, due to technical developments, such as expression arrays and next generation sequencing, that have resulted in the ability to interrogate biologic systems at a global level and open the door for implementing personalized medicine approaches for the treatment of complex disease. Second, new computational and mathematical approaches, such as network modeling, are being developed to extract biologic information from high throughput and other data. And, finally, there is a growing realization that reductionist approaches will not, alone, allow us to fully address problems such as the genetic and environmental interaction in common forms of heart disease and diabetes. The Board of Directors has selected Drs. A. Jake Lusis, Margrit Schwarz and Roger Newton to be the Co- Chairs of the meeting. All three are members of the Kern Board of Directors. Dr. Lusis is Professor of Human Genetics at the University of California, Los Angeles. His research has focused on the genetics of metabolic and cardiovascular diseases. Dr. Schwarz is Director of Atherosclerosis, Amgen, Inc. Her interests are in lipid metabolism and cardiovascular diseases. Roger Newton, Ph.D., is President of Esperion Therapeutics, Plymouth, MI. His interests are in pharmacology and cardiovascular disease. PUBLIC HEALTH RELEVANCE: The goal of this meeting is to provide attendees an opportunity to learn the latest advances in lipidomics and systems biology approaches, as well as, hear and discuss presentations on their relevance as tools for investigating cardiometabolic disease.